tradingkey.logo

Bolt Biotherapeutics Inc <BOLT.OQ> expected to post a loss of 36 cents a share - Earnings Preview

ReutersMay 9, 2025 1:18 PM
  • Bolt Biotherapeutics Inc BOLT.OQ BOLT.O is expected to show a fall in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025

  • The Redwood City California-based company is expected to report a 85.4% decrease in revenue to $767.5 thousand from $5.27 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Bolt Biotherapeutics Inc is for a loss of 36 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Bolt Biotherapeutics Inc is $1.13​, above​ its last closing price of $0.37. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.38

-0.38

Met

0

Sep. 30 2024

-0.34

-0.35

-0.40

Missed

-13.5

Jun. 30 2024

-0.52

-0.48

-0.46

Beat

4.2​

Mar. 31 2024

-0.50

-0.51

-0.28

Beat

45.1

​​Dec. 31 2023

-0.44

-0.48

-0.47

Beat

2.4

Sep. 30 2023

-0.50

-0.50

-0.43

Beat

14​

Jun. 30 2023

-0.50

-0.49

-0.48

Beat

1.4

Mar. 31 2023

-0.51

-0.51

-0.45

Beat

12.1

This summary was machine generated May 9 at 13:18 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI